| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.099 | 0.03 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.09 | 0.03 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.098 | 0.03 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.03 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.083 | 0.04 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.29 | 0.04 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.04 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.087 | 0.04 |